The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil
- PMID: 24976827
- PMCID: PMC4052518
- DOI: 10.1155/2014/858715
The SIAMS-ED Trial: A National, Independent, Multicentre Study on Cardiometabolic and Hormonal Impairment of Men with Erectile Dysfunction Treated with Vardenafil
Abstract
Increased cardiovascular risk has been associated with reduced response to proerectile drugs. The Italian Society of Andrology and Sexual Medicine (SIAMS) promoted an independent, multicenter study performed in 604 men (55 ± 12 yrs) suffering from erectile dysfunction (ED) to assess multiple health outcomes and response to 6-month vardenafil challenge in a real-life setting. Overall, 30.8% men had metabolic syndrome. Cardiovascular risk stratification revealed a greater number of ED subjects with moderate risk of a major adverse cardiovascular event than the general population (P < 0.01). Age-adjusted pulse pressure was positively correlated with ED severity and negatively with androgens and waist circumference (P < 0.01). A decline in total testosterone was observed with increasing arterial pulse pressure (P < 0.05), which was not accompanied by compensatory LH rise. Follow-up on 185 men treated with vardenafil in an nonrandomized, open, single-arm trial documented a significant rise in IIEF-5 (delta = 6.1 ± 4.8) that was maintained in men with high cardiovascular risk. Mild adverse events occurred in <5%, with no differences between cardiovascular risk classes. In summary, ED is a frequent symptom in patients with an elevated, but often unknown, risk of future cardiovascular events. Androgens predict vascular resistance in ED patients. Vardenafil's response and safety profile were preserved in subjects with higher cardiovascular risk.
Figures








Similar articles
-
Efficacy and safety of vardenafil for the treatment of erectile dysfunction in men with metabolic syndrome: results of a randomized, placebo-controlled trial.J Sex Med. 2011 Oct;8(10):2904-11. doi: 10.1111/j.1743-6109.2011.02383.x. Epub 2011 Jul 19. J Sex Med. 2011. PMID: 21771281 Clinical Trial.
-
Spotlight on vardenafil in erectile dysfunction.Drugs Aging. 2004;21(2):135-40. doi: 10.2165/00002512-200421020-00005. Drugs Aging. 2004. PMID: 14960129 Review.
-
Vardenafil: a review of its use in erectile dysfunction.Drugs. 2003;63(23):2673-703. doi: 10.2165/00003495-200363230-00010. Drugs. 2003. PMID: 14636086 Review.
-
Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism?Arab J Urol. 2015 Sep;13(3):162-8. doi: 10.1016/j.aju.2015.06.003. Epub 2015 Jul 7. Arab J Urol. 2015. PMID: 26413340 Free PMC article.
-
Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials.J Sex Med. 2011 Jan;8(1):261-71. doi: 10.1111/j.1743-6109.2010.02005.x. Epub 2010 Aug 30. J Sex Med. 2011. PMID: 20807322
Cited by
-
SIAMS survey on sexological screening during the assisted reproductive technologies in Italy.J Endocrinol Invest. 2015 Sep;38(9):999-1005. doi: 10.1007/s40618-015-0286-7. Epub 2015 Apr 18. J Endocrinol Invest. 2015. PMID: 25894866
-
[First data from a digital health app for erectile dysfunction].Urologie. 2022 Sep;61(9):971-981. doi: 10.1007/s00120-022-01872-x. Epub 2022 Jun 20. Urologie. 2022. PMID: 35925101 Free PMC article. German.
-
Lipidic extract of whole tomato reduces hyperplasia, oxidative stress and inflammation on testosterone-induced BPH in obese rats.Int Urol Nephrol. 2023 Mar;55(3):529-539. doi: 10.1007/s11255-022-03383-2. Epub 2022 Dec 4. Int Urol Nephrol. 2023. PMID: 36464759
-
Erectile Dysfunction and Oxidative Stress: A Narrative Review.Int J Mol Sci. 2025 Mar 27;26(7):3073. doi: 10.3390/ijms26073073. Int J Mol Sci. 2025. PMID: 40243750 Free PMC article. Review.
-
Reliability and validity of the Tibetan version of the International Prostate Symptom Score.World J Urol. 2023 May;41(5):1389-1394. doi: 10.1007/s00345-023-04368-1. Epub 2023 Apr 11. World J Urol. 2023. PMID: 37039905
References
-
- Lewis RW, Fugl-Meyer KS, Corona G, et al. Definitions/epidemiology/risk factors for sexual dysfunction. Journal of Sexual Medicine. 2010;7(4):1598–1607. - PubMed
-
- Esposito K, Giugliano F, Martedì E, et al. High proportions of erectile dysfunction in men with the metabolic syndrome. Diabetes Care. 2005;28(5):1201–1203. - PubMed
-
- De Berardis G, Franciosi M, Belfiglio M, et al. Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care. 2002;25(2):284–291. - PubMed
-
- Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. Journal of Urology. 2000;164(4):1188–1191. - PubMed
-
- Suetomi T, Kawai K, Hinotsu S, et al. Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men. Journal of Sexual Medicine. 2008;5(6):1443–1450. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources